Insider Buy Signals Confidence in Connect Biopharma Amid Volatile Shares and Clinical Milestones
James Huang’s sizable buy‑order in Connect Biopharma (CBHL) amid volatile pricing signals insider confidence and a fresh $20M equity round, offering hope that upcoming Phase 2 data may lift a struggling yet promising biopharma.
- Connect Biopharma Holdings Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read